Our new On the Radar report returns with fresh insights from Simos Simeonidis, PhD, Rodman & Renshaw's senior biotech analyst, who highlights biotech stocks which he believes will be good value
Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products
Exelixis Announces European Commission Approval of COTELLIC™ (Cobimetinib) for Use in Combination with Vemurafenib in Advanced BRAF V600 Mutation-Positive Melanoma
Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.
Allergan, seeking to burnish its reputation in R&D, bought into some early-stage treatments for autism and obsessive-compulsive disorder as it prepares to join forces with Pfizer in a massive merger.
Allergan and Rugen Therapeutics Announce Collaboration to Discover and Develop Ground-Breaking Medicines to Treat Autism Spectrum Disorders and Obsessive-Compulsive Disorders
Heptares Therapeutics, acquired by Japan's Sosei earlier this year, signed a deal with Teva Pharmaceutical to co-develop novel migraine treatments, getting in line for as much as $410 million.